Yohimbine Hydrochloride
Based on 10 publication(s) in Google Scholar
Yohimbine hydrochloride is an alpha-2 renal adenomatase receptor inhibitor, blocking pre- and post-contact alpha-2 renal adenomatase receptors, causing the release of renal adenoma and multiple sclerosis.
For research use only. We do not sell to patients.
- Purity: 99.92%
- CAS No.: 65-19-0
- Formula: C21H27ClN2O3
- Molecular Weight:390.90
-
Storage:
4°C, sealed storage, away from moisture
* In solvent : -80°C, 1 year; -20°C, 6 months (sealed storage, away from moisture)
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biological Activity
-
Chemical Information
-
Solvent & Solubility
- Purity & Documentation
- References
-
Help & FAQs
-
Neurotransmitter Receptor Compound Library
HY-L062
-
FDA Approved & Pharmacopeial Drug Library
HY-L066
-
Anti-Alzheimer's Disease Compound Library
HY-L069
-
Alkaloids Library
HY-L071
-
Neurodegenerative Disease-related Compound Library
HY-L086
-
Rare Diseases Drug Library
HY-L102
-
Antidepressant Compound Library
HY-L108
-
Plant-Sourced Natural Product Library
HY-L115
-
EMA-Approved Drug Library
HY-L116
-
Human Metabolite Library
HY-L123
-
Off-patent Drug Library
HY-L141
-
Antihypertensive Compound Library
HY-L145
-
Membrane Protein-targeted Compound Library
HY-L149
-
Membrane Receptor-targeted Compound Library
HY-L150
-
Bioactive Compound Library Max
HY-L181
-
MCE Bioactive Compound Library
HY-L001V
-
Natural Product Library Plus
HY-L021P
-
Drug Repurposing Compound Library Plus
HY-L035P
-
FDA-Approved Drug Library Plus
HY-L022P
-
FDA-Approved Drug Library Mini
HY-L022M
-
Bioactive Compound Library
HY-L001
-
RO5 Drug-like Natural Product Library
HY-L200
-
High-Throughput Bioactive Compound Library
HY-L205
-
High-Throughput Natural Product Library
HY-L206
-
Mass Spectrometry Human Metabolite Library
HY-L215
-
Lactylation Compound Library
HY-L249
-
Mass Spectrometry Natural Product Library
HY-L262
-
Natural Product and Natural Product-Like Compound Library
HY-L021M
-
Anti-Infection Compound Library
HY-L002
-
GPCR/G Protein Compound Library
HY-L006
-
Neuronal Signaling Compound Library
HY-L013
-
Natural Product Library
HY-L021
-
FDA-Approved Drug Library
HY-L022
-
Drug Repurposing Compound Library
HY-L035
-
Anti-diabetic Compound Library
HY-L040
-
Anti-Cardiovascular Disease Compound Library
HY-L046
-
Anti-COVID-19 Compound Library
HY-L052
Publications Citing Use of MedChemExpress (MCE) Yohimbine Hydrochloride
More- Nat Commun. 2025 May 16;16(1):4560. [Abstract]
- Adv Sci (Weinh). 2025 Jul;12(26):e2503739. [Abstract]
- Neurosci Bull. 2022 Apr;38(4):386-402. [Abstract]
- Mol Metab. 2026 May 26:102384. [Abstract]
- Cells. 2026 Jun 21;15(12):1120. [Abstract]
- Eur J Pharmacol. 2023 Dec 15:961:176174. [Abstract]
- Mol Med Rep. 2020 Jul;22(1):175-184. [Abstract]
- Mol Biol Rep. 2020 May;47(5):3629-3639. [Abstract]
- Exp Neurobiol. 2020 Oct 31;29(5):356-375. [Abstract]
- Afinidad. 2025.
Customer Validation & Images
-
In Vivo Efficacy Study
-
In Vivo Efficacy Study
-
In Vivo Efficacy Study
-
In Vivo Efficacy Study
-
Histological Imaging/Staining
All Adrenergic Receptor Isoforms
More
Biological Activity
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| Sf9 | IC50 |
3.67 nM
Compound: Yohimbine Hydrochloride
|
Displacement of [3H]MK9112 from human recombinant adrenergic alpha2A receptor expressed in insect Sf9 cells after 60 mins
Displacement of [3H]MK9112 from human recombinant adrenergic alpha2A receptor expressed in insect Sf9 cells after 60 mins
|
[PMID: 19788200] |
Please do not refer to only one article to determine the experimental conditions. It is recommended to determine the optimal experimental conditions (animal strain, age, dosage, frequency and cycle, detection time and indicators, etc.) through preliminary experiments before the formal experiment.
Yohimbine Hydrochloride can be used in animal modeling to create hypertension models. Administering yohimbine hydrochloride (0.2 mg/kg, intraperitoneally) to rats 1 hour before stress each day for 14 consecutive days, followed by immersing the rats in cold water, significantly reduces sexual arousal and libido, as evidenced by increased latency and intervals. Reduced mating activity can be confirmed by decreased levels of testosterone, luteinizing hormone (LH), and follicle-stimulating hormone (FSH), along with a decline in testicular cholesterol content in the rats. Treatment with yohimbine significantly enhances sexual arousal and performance and corrects the impact of stress on mating behavior in male rats[1].
Administration: 1 mg/kg• i.v.• a single dose for 5 min[1]
Rat: SHRs and WKY• male• 20-week-old• weighing 300-350 g[4]
Administration: 2 mg/kg• i.p.• daily for 2 weeks[4]
(2) Yohimbine (Hydrochloride) was dissolved in distilled water and dilutions made up in normal saline (NaCl 0.9%)[1].
(3) Before administration, animals were housed four per cage with free access to water and standard laboratory rat chow (Purina). The colony room had a temperature of 24±1°C, humidity of 45-55% and light/dark cycle (lights on 07:00-19:00)[4].
Blood pressure change: Yohimbine (Hydrochloride) reduced significantly the heart rate in spontaneously hypertensive rats (SHRs)[4].
Pathological changes: Yohimbine (Hydrochloride) elicited a marked, significant increase in receptor density over the outer strip of the outer medulla[4].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
| NCT Number | Sponsor | Condition | Start Date |
Phase
|
|---|---|---|---|---|
| NCT01329991 | Plexxikon| | 2011-05 | PHASE1 |
Chemical Information
-
CAS No. 65-19-0
-
Appearance Solid
-
Molecular Weight 390.90
-
Formula C21H27ClN2O3
-
Color White to light yellow
-
SMILES
[H][C@]12C(NC3=C4C=CC=C3)=C4CCN1C[C@@]5(CC[C@H](O)[C@H](C(OC)=O)[C@]5(C2)[H])[H].[H]Cl
-
Structure Classification
-
Initial Source
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
4°C, sealed storage, away from moisture
* In solvent : -80°C, 1 year; -20°C, 6 months (sealed storage, away from moisture)
Publications (10)
-
Journal Impact Factor
-
Most Recent
-
Nat Commun
A ventral pallidum-locus coeruleus-lateral hypothalamus pathway modulates brain arousal in freely behaving and isoflurane-anesthetized male mice. [Abstract]2025 May 16;16(1):4560. PMID: 40379709
Yohimbine Hydrochloride purchased from MedChemExpress. Usage Cited in: Nat Commun. 2025 May 16;16(1):4560. [Abstract]
% time, number of episodes, and total duration in each motor state between 1 to 1.5 h after Vehicle, CNO and CNO + Yohembine (10 μM, 200 nl) injection.
Yohimbine Hydrochloride purchased from MedChemExpress. Usage Cited in: Nat Commun. 2025 May 16;16(1):4560. [Abstract]
Representative traces of EEG signals, % power of EEG waves, and EEG power spectrum between 0.5 and 1.5 h after injection of vehicle, CNO, or CNO+Yohimbine (YOH, 10 μM, 200 nl) into the LH, in freely behaving mice.
Yohimbine Hydrochloride purchased from MedChemExpress. Usage Cited in: Nat Commun. 2025 May 16;16(1):4560. [Abstract]
Time to LORR in 1.4% isoflurane and RORR and motor score recovery after 20 min anesthesia with 1.4% isoflurane after delivery of Vehicle, CNO and CNO+Yohimbine (YOH, 10 μM, 200 nl) into the LH.
-
Adv Sci (Weinh)
The Locus Coeruleus-Periaqueductal Gray GABAergic Projection Regulates Comorbid Pain and Depression. [Abstract]2025 Jul;12(26):e2503739. PMID: 40192524 -
Neurosci Bull
Referred Somatic Hyperalgesia Mediates Cardiac Regulation by the Activation of Sympathetic Nerves in a Rat Model of Myocardial Ischemia. [Abstract]2022 Apr;38(4):386-402. PMID: 35471719 -
Mol Metab
Vagal control of the brain-esophagus axis ameliorates stress-induced esophageal motility dysfunction in male mice. [Abstract]2026 May 26:102384. PMID: 42203107 -
Cells
Effects of Xylazole on cAMP and Monoamine Neurotransmitters in Rats: In Vitro and In Vivo. [Abstract]2026 Jun 21;15(12):1120. PMID: 42346147 -
Eur J Pharmacol
A novel dopamine D2 receptor-NR2B protein complex might contribute to morphine use disorders. [Abstract]2023 Dec 15:961:176174. PMID: 37939993
Yohimbine Hydrochloride purchased from MedChemExpress. Usage Cited in: Eur J Pharmacol. 2023 Dec 15:961:176174. [Abstract]
LV ejection fraction, heart rate, and cardiac output in control rats, and in MI rats in response to electrical stimulation (ES, 3 mA, 15 Hz, 30 s), intradermal injection of yohimbine (YOB, 5 µg/20 µL, an α2AR antagonist) and dexmedetomidine (DEX, 5 µg/20 µL, a potent and selective α2AR agonist that inhibits norepinephrine release from synaptic vesicles) at the sensitized area (PC6) on the forelimb.
-
Mol Med Rep
Dexmedetomidine alleviated sepsis‑induced myocardial ferroptosis and septic heart injury. [Abstract]2020 Jul;22(1):175-184. PMID: 32377745
Yohimbine Hydrochloride purchased from MedChemExpress. Usage Cited in: Mol Med Rep. 2020 Jul;22(1):175-184. [Abstract]
Heart hematoxylin and eosin staining. Cell nuclei appeared as blue dominant dots due to CLP-induced inflammation, while normal cell nuclei were navy-blue. Dex treatment reduced inflammatory cells and Yohimbine (YOH, 1 mg/kg) reversed the protective effects of Dex.
Yohimbine Hydrochloride purchased from MedChemExpress. Usage Cited in: Mol Med Rep. 2020 Jul;22(1):175-184. [Abstract]
Yohimbine (YOH, 1 mg/kg). Changes in the protein expression of iNOS and P53. Sepsis was achieved by CLP. Data are presented as the mean ± SEM. n=6 per group.
-
Mol Biol Rep
Dexmedetomidine alleviates H2O2-induced oxidative stress and cell necroptosis through activating of α2-adrenoceptor in H9C2 cells. [Abstract]2020 May;47(5):3629-3639. PMID: 32342432 -
Exp Neurobiol
Neuroprotection of the Developing Brain by Dexmedetomidine Is Mediated by Attenuating Single Propofol-induced Hippocampal Apoptosis and Synaptic Plasticity Deficits. [Abstract]2020 Oct 31;29(5):356-375. PMID: 33154198 -
Solvent & Solubility
DMSO : 8.75 mg/mL (22.38 mM; ultrasonic and warming and heat to 60°C; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
H2O : 3.33 mg/mL (8.52 mM; Need ultrasonic)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 1 year; -20°C, 6 months (sealed storage, away from moisture). When stored at -80°C, please use it within 1 year. When stored at -20°C, please use it within 6 months.
* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 1 year; -20°C, 6 months (sealed storage, away from moisture). When stored at -80°C, please use it within 1 year. When stored at -20°C, please use it within 6 months.
* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 2.5 mg/mL (6.40 mM); Clear solution
This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: ≥ 2.5 mg/mL (6.40 mM); Clear solution
This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
-
%DMSO +
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
-
%+
-
+%Tween-80 + +
-
%Saline +
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Working solution concentration: 0.22 mg/mL
Method for preparing stock solution: mg drug dissolved in μL DMSO. Stock solution concentration: mg/mL. * In solvent : -80°C, 1 year; -20°C, 6 months (sealed storage, away from moisture)
1. Take μL DMSO stock solution;
2. Add μL .
μL , mix evenly;
3. Then add μL Tween 80, mix evenly;
4. Then add μL
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
Purity & Documentation
-
Data Sheet (286 KB)
-
SDS (480 KB)
- English - EN (480 KB)
- Français - FR (480 KB)
- Deutsch - DE (480 KB)
- Norwegian - NO (480 KB)
- Español - ES (480 KB)
- Swedish - SV (480 KB)
- Italian - IT (480 KB)
- Korean - KR (480 KB)
- Portuguese - PT (480 KB)
-
Handling Instructions (2659 KB)
References
[1]. Docherty JR. Yohimbine antagonises α1A- and α1D-adrenoceptor mediated components in addition to the α2A-adrenoceptor component to pressor responses in the pithed rat. Eur J Pharmacol. 2012 Mar 15;679(1-3):90-4. [Content Brief]
[2]. Damase-Michel C, et al. The effect of yohimbine on sympathetic responsiveness in essential hypertension. Eur J Clin Pharmacol. 1993;44(2):199-201. [Content Brief]
[3]. Musso NR, et al. Yohimbine effects on blood pressure and plasma catecholamines in human hypertension. Am J Hypertens. 1995 Jun;8(6):565-71. [Content Brief]
[4]. Sáiz J, et al. Yohimbine-induced alterations in alpha(2)-adrenoceptors in kidney regions of the spontaneously hypertensive rats: an autoradiographic analysis. Pharmacol Rep. 2008 May-Jun;60(3):391-8. [Content Brief]
[5]. Docherty JR, et al. Yohimbine antagonises α1A- and α1D-adrenoceptor mediated components in addition to the α2A-adrenoceptor component to pressor responses in the pithed rat. Eur J Pharmacol. 2012 Mar 15;679(1-3):90-4. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 1 year; -20°C, 6 months (sealed storage, away from moisture). When stored at -80°C, please use it within 1 year. When stored at -20°C, please use it within 6 months.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| H2O / DMSO | 1 mM | 2.5582 mL | 12.7910 mL | 25.5820 mL | 63.9550 mL |
| 5 mM | 0.5116 mL | 2.5582 mL | 5.1164 mL | 12.7910 mL | |
| DMSO | 10 mM | 0.2558 mL | 1.2791 mL | 2.5582 mL | 6.3955 mL |
| 15 mM | 0.1705 mL | 0.8527 mL | 1.7055 mL | 4.2637 mL | |
| 20 mM | 0.1279 mL | 0.6395 mL | 1.2791 mL | 3.1977 mL |
* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.
Yohimbine Hydrochloride Related Classifications
HY-N0127 Related Classifications
Powered by Bioz